Anti-inflammatory activity of novel thiosemicarbazone compounds indole-based as COX inhibitors
作者:Íris T. T. Jacob、Fabiana O. S. Gomes、Mirelly D. S. de Miranda、Sinara M. V. de Almeida、Iranildo J. da Cruz-Filho、Christina A. Peixoto、Teresinha G. da Silva、Diogo R. M. Moreira、Cristiane M. L. de Melo、Jamerson F. de Oliveira、Maria C. A. de Lima
DOI:10.1007/s43440-021-00221-7
日期:2021.6
In this article, a series of 20 new thiosemicarbazone derivatives containing indole were synthesized and evaluated for their anti-inflammatory potential. The compounds were obtained through a synthetic route of only two steps, with yields that varied between 33.6 and 90.4%, and characterized by spectroscopic and spectrometric techniques. An initial screening through the lymphoproliferation assay revealed that compounds LT76, LT81, and LT87 were able to inhibit lymphocyte proliferation, with CC50 of 0.56 ± 0.036, 0.9 ± 0.01 and 0.5 ± 0.07 µM, respectively, better results than indomethacin (CC50 > 12 µM). In addition, these compounds were able to suppress the in-vitro production of TNF-α and NO, in addition to stimulating the production of IL-4. Reinforcing in-vitro assays, the compounds were able to inhibit COX-2 similar to Celecoxib showing greater selectivity for this isoform (LT81 SI: 23.06 versus Celecoxib SI: 11.88). Animal studies showed that compounds LT76 (64.8% inhibition after 6 h), LT81 (89% inhibition after 6 h) and LT87 (100% inhibition after 4 h) were able to suppress edema in mice after inoculation carrageenan with greater potency than indomethacin, and immunohistochemistry revealed that the groups treated with LT76, LT81 and LT87 reduced the expression of COX-2, similar or better results when compared to indomethacin. Complementarily, in-silico studies have shown that these compounds have a good pharmacokinetic profile, for respecting the parameters of Lipinski and Veber, showing their good bioavailability. These results demonstrate the potency of thiosemicarbazone derivatives containing indole and confirm their importance as scaffolds of molecules with notorious anti-inflammatory activity.
在这篇文章中,合成了一系列含有吲哚的20种新型噻二唑半卡巴脘衍生物,并评估了它们的抗炎潜力。这些化合物通过仅两步的合成路线获得,产率在33.6%至90.4%之间,并通过光谱学和光谱测量技术进行表征。通过淋巴增生试验的初步筛选发现,化合物LT76、LT81和LT87能够抑制淋巴细胞增生,CC50分别为0.56 ± 0.036、0.9 ± 0.01和0.5 ± 0.07 µM,结果优于吲哚美辛(CC50 > 12 µM)。此外,这些化合物还能抑制体外TNF-α和NO的产生,并刺激IL-4的生成。加强体外试验显示,这些化合物能抑制COX-2,类似塞来昔布,具有更高的选择性(LT81 SI: 23.06,塞来昔布SI: 11.88)。动物研究表明,化合物LT76(6小时后抑制64.8%)、LT81(6小时后抑制89%)和LT87(4小时后抑制100%)能够在卡拉胶接种后抑制小鼠水肿,效果优于吲哚美辛,免疫组化显示,用LT76、LT81和LT87处理的组减少了COX-2的表达,与吲哚美辛相比结果相似或更好。此外,计算研究显示这些化合物具有良好的药代动力学特性,遵守Lipinski和Veber参数,显示出良好的生物利用度。这些结果证明了含有吲哚的噻二唑半卡巴脘衍生物的效力,并确认了它们作为具有显著抗炎活性分子骨架的重要性。